[
  {
    "ts": null,
    "headline": "Novo’s New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way.",
    "summary": "Catalent says it worked on more than half of the new drugs approved by the FDA over the past 10 years.",
    "url": "https://finnhub.io/api/news?id=6e41469b058b9c11b165af6146853312a5b25708747e4f88669c4997b6b4886f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734386580,
      "headline": "Novo’s New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way.",
      "id": 132018647,
      "image": "https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Catalent says it worked on more than half of the new drugs approved by the FDA over the past 10 years.",
      "url": "https://finnhub.io/api/news?id=6e41469b058b9c11b165af6146853312a5b25708747e4f88669c4997b6b4886f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors despite losses on the day",
    "summary": "Eli Lilly & Co. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=2e8a56d768e98e8581c45eab791ce714e7bdaf193453ac89b9f4051dae45c6cc",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734366780,
      "headline": "Eli Lilly & Co. stock outperforms competitors despite losses on the day",
      "id": 132064408,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=2e8a56d768e98e8581c45eab791ce714e7bdaf193453ac89b9f4051dae45c6cc"
    }
  },
  {
    "ts": null,
    "headline": "Insurer Stocks Tumble. Trump Echoes Drug Industry Attacks on PBMs.",
    "summary": "Insurer Stocks Tumble. Trump Echoes Drug Industry Attacks on PBMs.",
    "url": "https://finnhub.io/api/news?id=f41e72a950ed1b2dd59a424074df6b51376a2e758cb040196c242cef41aab89b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734358920,
      "headline": "Insurer Stocks Tumble. Trump Echoes Drug Industry Attacks on PBMs.",
      "id": 132064409,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Insurer Stocks Tumble. Trump Echoes Drug Industry Attacks on PBMs.",
      "url": "https://finnhub.io/api/news?id=f41e72a950ed1b2dd59a424074df6b51376a2e758cb040196c242cef41aab89b"
    }
  },
  {
    "ts": null,
    "headline": "Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?",
    "summary": "The weight-loss drugs battle has grabbed Wall Street's attention and stoked shares of Eli Lilly and Novo Nordisk. But others are coming.",
    "url": "https://finnhub.io/api/news?id=6cb607d103415376d9d07c90278dcd33f958e24cf9dd571a2bc12ffbc7065c56",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734354059,
      "headline": "Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?",
      "id": 132010903,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The weight-loss drugs battle has grabbed Wall Street's attention and stoked shares of Eli Lilly and Novo Nordisk. But others are coming.",
      "url": "https://finnhub.io/api/news?id=6cb607d103415376d9d07c90278dcd33f958e24cf9dd571a2bc12ffbc7065c56"
    }
  },
  {
    "ts": null,
    "headline": "EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease",
    "summary": "The CHMP's opinion is based on late-stage data, which show that LLY's Omvoh is effective in Crohn's disease patients with or without prior biologic failure.",
    "url": "https://finnhub.io/api/news?id=521b4a3c62765effaf186c598570ecb2b51c468ba4416fff3cee3a4eba952d87",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734351780,
      "headline": "EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease",
      "id": 132011828,
      "image": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The CHMP's opinion is based on late-stage data, which show that LLY's Omvoh is effective in Crohn's disease patients with or without prior biologic failure.",
      "url": "https://finnhub.io/api/news?id=521b4a3c62765effaf186c598570ecb2b51c468ba4416fff3cee3a4eba952d87"
    }
  },
  {
    "ts": null,
    "headline": "EMA CHMP recommends Lilly’s Crohn’s therapy for EU approval",
    "summary": "The recommendation is based on outcomes from the Phase III VIVID-1 trial.",
    "url": "https://finnhub.io/api/news?id=ad256e37ded881bc088ab4e3743372c7b1633b6efbfa5e4320a05c95ee941129",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734347191,
      "headline": "EMA CHMP recommends Lilly’s Crohn’s therapy for EU approval",
      "id": 132010942,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2024/12/Pharma-2-Lilly-Shutterstock_2199932579.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The recommendation is based on outcomes from the Phase III VIVID-1 trial.",
      "url": "https://finnhub.io/api/news?id=ad256e37ded881bc088ab4e3743372c7b1633b6efbfa5e4320a05c95ee941129"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Omvoh recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease",
    "summary": "INDIANAPOLIS - Eli Lilly and Company announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for Omvoh , an...",
    "url": "https://finnhub.io/api/news?id=fe41157d656acb23196c8219eb7326f2c13dd302707ef1de104951a6c4e9efa9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734347133,
      "headline": "Lilly's Omvoh recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease",
      "id": 132012104,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "INDIANAPOLIS - Eli Lilly and Company announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for Omvoh , an...",
      "url": "https://finnhub.io/api/news?id=fe41157d656acb23196c8219eb7326f2c13dd302707ef1de104951a6c4e9efa9"
    }
  },
  {
    "ts": null,
    "headline": "Why the investor craze for Ozempic and rival weight-loss drugs may resume next year",
    "summary": "Why the investor craze for Ozempic and rival weight-loss drugs may resume next year",
    "url": "https://finnhub.io/api/news?id=da179e29be3ee4d6115ac3020fb8ebb4268901026276d3d747cf68ecb5502e43",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734344280,
      "headline": "Why the investor craze for Ozempic and rival weight-loss drugs may resume next year",
      "id": 132064410,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Why the investor craze for Ozempic and rival weight-loss drugs may resume next year",
      "url": "https://finnhub.io/api/news?id=da179e29be3ee4d6115ac3020fb8ebb4268901026276d3d747cf68ecb5502e43"
    }
  },
  {
    "ts": null,
    "headline": "The Weight-Loss Drug Market Is Heading for a Reckoning This Week",
    "summary": "The Weight-Loss Drug Market Is Heading for a Reckoning This Week",
    "url": "https://finnhub.io/api/news?id=5165c3e61a9966f08312d80e00fb4d72e58b3358c7e4414a2837e8c866b56d85",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734338820,
      "headline": "The Weight-Loss Drug Market Is Heading for a Reckoning This Week",
      "id": 132064411,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "The Weight-Loss Drug Market Is Heading for a Reckoning This Week",
      "url": "https://finnhub.io/api/news?id=5165c3e61a9966f08312d80e00fb4d72e58b3358c7e4414a2837e8c866b56d85"
    }
  },
  {
    "ts": null,
    "headline": "The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect.",
    "summary": "The FDA is slated to reveal whether Eli Lilly’s supply of its obesity drug Zepbound can meet U.S. demand.",
    "url": "https://finnhub.io/api/news?id=5f64d334ff0eac1334d6e344892e08ad067dd38fde215d48568b71b8595324f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734332400,
      "headline": "The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect.",
      "id": 132009459,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The FDA is slated to reveal whether Eli Lilly’s supply of its obesity drug Zepbound can meet U.S. demand.",
      "url": "https://finnhub.io/api/news?id=5f64d334ff0eac1334d6e344892e08ad067dd38fde215d48568b71b8595324f6"
    }
  },
  {
    "ts": null,
    "headline": "Altimmune 2025: Redefining Obesity And MASH Treatment",
    "summary": "Altimmune is redefining success in both obesity and MASH to position Pemvidutide in blue ocean categories. Read why I rate ALT stock a Buy now.",
    "url": "https://finnhub.io/api/news?id=ed55edde371bee8c7944e37ff4cd9da32bc43eb73ae413bbe17d330bbcac6d71",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734318863,
      "headline": "Altimmune 2025: Redefining Obesity And MASH Treatment",
      "id": 132008513,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359132436/image_1359132436.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Altimmune is redefining success in both obesity and MASH to position Pemvidutide in blue ocean categories. Read why I rate ALT stock a Buy now.",
      "url": "https://finnhub.io/api/news?id=ed55edde371bee8c7944e37ff4cd9da32bc43eb73ae413bbe17d330bbcac6d71"
    }
  }
]